<DOC>
	<DOCNO>NCT02520570</DOCNO>
	<brief_summary>1 . Investigate application ulinastatin real practice clinic . ( eg : population character , usage dosage , course treatment , etc ) 2 . Analysis incidence adverse drug reaction /adverse event ulinastatin , collect main clinical manifestation , treatment , outcome , influence factor ; provide evidence improve recommend medication plan ulinastatin . 3 . Evaluate safety ulinastatin , obtain scientific conclusion , provide evidence appropriate medication administration department health authority .</brief_summary>
	<brief_title>Post-market Safety Reassessment Ulinastatin Injection</brief_title>
	<detailed_description>In order find application ulinastatin real practice clinic , identify high risk group adverse event/adverse drug reaction calculate adverse event/adverse drug reaction incidence rate , large sample size clinical trial design . This trial observational study . The investigator would screen several hospital different province prospectively collect main clinical manifestation , treatment , outcome , influence factor patient use ulinastatin either general clinical department ICU . This study would expect provide evidence appropriate medication administration department health authority .</detailed_description>
	<mesh_term>Drug-Related Side Effects Adverse Reactions</mesh_term>
	<mesh_term>Urinastatin</mesh_term>
	<mesh_term>Trypsin Inhibitors</mesh_term>
	<criteria>Patients ulinastatin treat</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>